Perspective Therapeutics, Inc. (CATX)

In October 2025, the stock tumbled 30.5% after presenting updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET. In January 2026, the stock experienced sharp gains tied to pipeline enthusiasm. In February 2026, Perspective Therapeutics announced the pricing of a $175 million underwritten offering of common stock and pre-funded warrants at $3.79 per share. In March 2026, the company reported full-year 2025 results and a business update, with the stock declining -5.2% the day following the earnings announcement. The stock has also shown high volatility over the past three months.

Information regarding specific demand seasonality for Perspective Therapeutics, Inc.'s products and services is not readily available. Demand for these would be driven by clinical trial progress, regulatory approvals, and market adoption post-commercialization, rather than traditional seasonal consumer demand. The company's focus is on developing advanced treatments for cancers, which typically have consistent demand based on disease prevalence rather than seasonal fluctuations.

Perspective Therapeutics, Inc. (CATX) is a clinical-stage radiopharmaceutical development company focused on pioneering advanced treatments for various cancers. The company's technology utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver radiation to cancer cells via targeting peptides. Perspective Therapeutics is also developing imaging diagnostics that incorporate the same targeting peptides, enabling a theranostic approach. Key products include VMT-α-NET (SSTR2) in Phase 1/2a trials for neuroendocrine tumors, VMT01 (MC1R) in Phase 1/2a trials for metastatic melanoma, PSV359 (FAP-α) targeting multiple solid tumors, a 212Pb generator, and Cesium-131 brachytherapy seeds.

Perspective Therapeutics, Inc. is headquartered in Seattle, Washington, United States. The company is also building a distributed manufacturing network for its 212Pb generators, with facilities in Iowa and New Jersey, and new sites planned for Houston, Chicago, and Los Angeles.

Perspective Therapeutics' brand reputation is influenced by its clinical trial progress and financial activities. Analyst sentiment is generally positive, with a consensus "Buy" rating. Positive clinical trial data for VMT-α-NET has contributed positively to its reputation. The $175 million stock offering in February 2026 was seen as a move to bolster cash reserves. The stock has experienced high volatility. The company's earnings reports are closely watched and can influence perception.

Perspective Therapeutics, Inc. has a mixed ownership structure, with institutional, individual, and retail investors. As of March 27, 2026, 121 institutional owners and shareholders held a total of 36,557,241 shares. Lantheus Alpha Therapy LLC is noted as the largest individual shareholder, owning 116.77 million shares, representing 102.49% of the company. Approximately 32.11% of the company is owned by institutional shareholders, 106.49% by Perspective Therapeutics insiders, and 0.00% by retail investors according to one source.